SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its development partner Merck & Co., Inc. will present preliminary scientific data on investigational vaccines, including results from a tolerability study using Inovio’s MedPulser® DNA Delivery System, during the Fifth World Congress on Vaccines, Immunization and Immunotherapy being held at Fairmont The Queen Elizabeth Hotel in Montreal, Canada, Nov. 6-8, 2006.
